ScholarWorks@Korea University College of Medicine: Lee, Juneyoung

Detailed Information

Lee, Juneyoung (이준영)

의과대학 (Department of Biostatistics)

Research Area: Causal Inference, Clinical Trial Methodology, Statistical Modeling

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

stroke:24||Stroke:22||cerebral infarction:14||ischemic stroke:11||Acute ischemic stroke:11||Korea:11||prognosis:10||blood pressure:9||outcome:9||Korean:8||thrombolysis:8||Quality of life:8||metabolic syndrome:7||risk factors:7||acute ischemic stroke:7||atrial fibrillation:7||Mortality:7||metaanalysis:6||Prognosis:6||systematic review:5||Prevalence:5||aspirin:5||mortality:5||cancer:5||prevalence:5||Metaanalysis:5||Thrombolysis:5||Ischemic stroke:5||incidence:5||Epidemiology:5||propensity score:4||magnetic resonance imaging:4||Acute stroke:4||Diabetes mellitus:4||myocardial infarction:4||atherosclerosis:4||hypertension:4||breast:4||recurrence:4||Incidence:4||없음:4||breast neoplasms:4||insulin resistance:4||Systematic review:3||statin:3||암:3||Davies&apos:3||technology:3||호스피스:3||Diabetes:3||Body mass index:3||Measure of imbalance:3||Guideline:3||algorithm:3||clopidogrel:3||endovascular treatment:3||US:3||Vitamin D:3||cohort study:3||Outcome:3||Risk factor:3||quality of life:3||ultrasound (US):3||Unbalanced design:3||Neoplasms:3||heart rate:3||diagnosis:3||risk:3||intracranial atherosclerosis:3||delirium:3||outcome assessment:2||Breast neoplasms:2||Endovascular Treatment:2||acute myocardial infarction:2||acute stroke:2||Generalized linear models:2||Glenoid component:2||Micromotion:2||percutaneous coronary intervention:2||Recanalization:2||elderly:2||Child:2||Survival:2||endovascular recanalization:2||유병률:2||prediction:2||epidemiology:2||Inferior tilt:2||prevention:2||finite element analysis:2||anemia:2||probucol:2||ankylosing spondylitis:2||prognostic factor:2||anticoagulants:2||.:2||gastric cancer:2||Outcome assessment:2||apolipoprotein AI:2||apolipoprotein B:2||Atrial fibrillation:2||quality:2||guideline adherence:2||Revascularization:2||quality of care:2||Carcinoma:2||Logarithmic link function:2||COVID19:2||hemorrhage:2||Pain:2||revascularization:2||Terminal care:2||Terminally ill:2||Risk factors:2||secondary prevention:2||secondary stroke prevention:2||sensitivity:2||specificity:2||breast cancer:2||breast, US:2||Epilepsy:2||stroke severity:2||survival:2||Thrombolytic therapy:2||cardiovascular disease:2||Depression:2||intracranial:2||N/A:2||Biomechanical testing:2||Cerebral infarction:2||cerebral hemorrhage:2||Diagnostic test accuracy:2||Ferritins:2||Cardiovascular disease:2||Secondary prevention:2||Elderly:2||transient ischemic attack:2||Triglycerides:2||cilostazol:2||Magnetic resonance imaging:2||clinical trial:2||leukoaraiosis:2||Type 2 diabetes:2||cohort studies:2||type 2 diabetes:2||ultrasound (US), comparative studies:2||Dipeptidyl peptidase4 inhibitors:2||comparative studies:2||Hospice care:2||mammography:2||Endstage renal disease:2||Fracture:2||microbleeds:2||Cardiovascular diseases:2||Variance components:2||white matter hyperintensities:2||Vascular cognitive impairment:2||Vascular events:2||Primary stability:2||death:2||Obesity:2||Functional outcome:2||말기 돌봄:2||diabetes:2||Breast cancer:2||Endovascular recanalization:1||Endovascular revascularization:1||Endovascular therapy:1||Endovascular treatment:1||Epidemiologic indices:1||Event Outcome:1||Exercise:1||Ezetimibe:1||False Negativity:1||False Positivity:1||Fasting Triglycerides:1||Fatty liver:1||Femoral head:1||First aid:1||Fluid:1||Foetal outcome:1||Fourstage nested experiment:1||Frailty:1||Functional MRI:1||Futile reperfusion:1||GUIDELINES:1||Generalized Linear Models:1||Glucose:1||Green space:1||Greenness:1||HBV:1||HER2 gene:1||Hair:1||Healing:1||Health:1||Health Insurance Review &:1||Health knowledge:1||Health outcome:1||Heart Rate Variability:1||Heart diseases:1||Heart failure:1||Hematopoietic stem cell transplantation:1||High blood pressure:1||Histological analysis:1||Hong Kong Liver Cancer:1||Hospice:1||Hospices:1||Hydrocortisone:1||HydroxymethylglutarylCoA reductase inhibitors:1||Hyperacute treatment:1||Hypertension:1||Hypogonadism:1||ICUs:1||INR Control:1||Idiopathic avascular necrosis:1||Immobilized pH gradients:1||Infarct volume:1||Inflammation indices:1||Insulin resistance:1||Insurance:1||Insurance claim review data:1||Intensive care unit:1||Interhospital transfer:1||International normalized ratio:1||Interrupted timeseries analysis:1||Intimamedial thickness:1||Intracerebral haemorrhage:1||Intracranial:1||Intracranial atherosclerosis:1||Intravenous recombinant tissue plasminogen activator:1||Intravenous thrombolysis:1||Inverted nested design:1||Ischemia:1||Ischemic Attack:1||Ischemic Stroke:1||Item response theory:1||Itraconazole:1||Job Satisfaction:1||Knowledge:1||Korean External Quality Assessment Scheme:1||Ku70:1||LDL:1||LDL cholesterol:1||LDLcholesterol:1||LDLT:1||Large artery stenoocclusion:1||Left ventricular systolic dysfunction:1||Leptin:1||Letrozole:1||Level of significance:1||Life Expectancy:1||Life expectancy:1||Life style:1||Liver transplantation:1||Long term adverse effects:1||Longterm:1||Longitudinal:1||Longitudinal study:1||Low molecular weight plasma proteins:1||Lymphocytes:1||M.D.:1||MELD:1||MELDNa:1||MOF:1||MRE:1||MRI:1||MTT:1||Magnesium:1||Magnetic Resonance Imaging:1||Major depressive disorder:1||Major high molecular weight plasma proteins:1||Mammary:1||Maternal outcome:1||Matrix metalloproteinase:1||Maximum likelihood:1||Maximum likelihood estimation:1||Measure of Imbalance:1||Measure of imbalance Oneway random model:1||Meat consumption:1||Medical cost:1||Medical cost 대상 및 방법1. 대상 본 연구는 1994년 12월 1일부터 2002년 12월 31일까지 당뇨병을 주 또는 부상병으로 건강보험심사평가원에 1회 이상 청구된 3:1||Metabolic syndrome:1||Metabolic syndrome X:1||Mild stroke:1||Minor Ischemic Stroke:1||Minor stroke definition:1||Mixed model:1||Molecular imaging:1||Molecular targeted therapy:1||Mononuclear leukocytes:1||Monte Carlo 모의 실험:1||MonteCarlo simulation:1||Motor skills:1||Mre11A protein:1||Multinational aspect:1||Multivariate analysis:1||Mycoses:1||Myocardial Infarction:1||NIHSS:1||NINDSTPA trials:1||NSAID:1||National Health Insurance:1||National Prevalence:1||National survey:1||Nationwide analysis:1||Neoplasm:1||Neoplasm staging:1||Nervous system diseases:1||Neuralgia:1||Nonfasting Triglycerides:1||Noninvasive diagnosis:1||Nonalcoholic fatty liver:1||Nonalcoholic fatty liver disease:1||Nonalcoholic steatohepatitis:1||Nonlinear designs:1||Nursing Delirium Screening Scale:1||Observation study2003년에 전세계적으로 최소 1억 9천만명 이상의 환자가 있을 것으로 추정된 매우 흔한 질환이고 다양한 심혈관계 합병증들뿐만 아니라 족부절단:1||Observational study:1||Occupational health Korean J Prev Med 2004:1||Occupational performance skills:1||Oneway Random Model:1||Onychomycosis:1||Opioid analgesics:1||Oral anticoagulant:1||Organization:1||Organizational Commitment:1||Osteoporosis:1||Outcomes:1||Oxcarbazepine:1||Oxiracetam:1||PCI optimization:1||PCI outcomes:1||PCSK9 inhibitor:1||PROJECT:1||Palpation:1||Paraganglioma: Epidemiology:1||Paroxysmal nocturnal hemoglobinuria:1||Patient reported outcome measures:1||Patient satisfaction:1||Peripheral arterial disease:1||Pheochromocytoma:1||Physical illness:1||Physician practice patterns:1||Platelet aggregation inhibitors:1||Platycodon grandiflorum:1||Population attributable risk:1||Postprandial:1||Poststroke cognitive impairment:1||Power:1||Preceding intravenous thrombolysis:1||Prediction bias:1||Prediction capability:1||Prediction model:1||Predictors:1||Pregnancy:1||Pregnancy outcome:1||Pregnancy outcomes:1||Prevalence라 20세 이상 성인의 당뇨병 유병률은 연령 보정후 7.6%로 270만명으로 추산되어 1992년 조사자료를 토대로 한 세계보건기구의 예측보다 더 빠른 증가를 보이고 있다2:1||Primary 62J10:1||Probucol:1||Procalcitonin:1||Processing skills:1||Prognostic model:1||Quality management:1||Quality of Life:1||Quality of health care:1||Quantile dispersion graphs:1||Quantile plots:1||RISK:1||Recanalization therapy:1||Recurrent event:1||Registries:1||Renal cell:1||Reninangiotensin system:1||Republic of Korea:1||Respiration:1||Response surface methodology:1||Reverse shoulder arthroplasty:1||Reverse total shoulder arthroplast:1||Reverse total shoulder arthroplasty:1||Risk:1||Risk Prediction:1||Risk management:1||Risk score:1||Robustness:1||Rosuvastatin:1||Rotator cuff:1||SARSCoV2:1||SCALE:1||SIRS:1||SURVIVAL:1||Satisfaction:1||Scaled meansquared error of prediction:1||Score:1||Secondary 62K99:1||Selfmanagement:1||Sensitivity analysis:1||Sensory processing ability:1||Serum:1||Side effects and adverse reactions:1||Simulated computer model:1||Simulation:1||Smaller baseplate:1||Smoking:1||South Korea:1||Staggered nested design:1||Standardization of Diagnostic Tests:1||Statin:1||Statins:1||Statistics:1||Stenosis and occlusion:1||Stratified twostage cluster sampling:1||Stroke Center:1||Stroke Recurrence:1||Stroke progression:1||Stroke recurrence:1||Stroke registry:1||Stroke severity:1||Stroke subtype:1||Stroke treatment:1||Stroke volume:1||Subarachnoid Hemorrhage:1||Suicide:1||Sulfonylurea:1||Survival analysis:1||Survival rate:1||Symptomatic:1||TNF inhibitor:1||TRIAL:1||TTSfentanyl:1||Target goal:1||Temperature:1||Terbinafine:1||Terminal Care:1||Terminal cancer:1||Terminal cancer patients:1||Testosterone Deficiency Syndrome:1||Testosterone Undecanoate:1||Therapeutic benefit:1||Thrombectomy:1||Thyroid neoplasms:1||Tibia:1||Torsion:1||Trace elements:1||Transactional Leadership:1||Transesophageal echocardiography:1||Transfer:1||Transferredin:1||Transformational Leadership:1||Transient:1||Treatment:1||Treatment adherence and compliance:1||Treatment outcome:1||Trend:1||Type 2:1||Ultrasonography:1||Unbalanced Data:1||Unbalanced data:1||Underweight:1||Unemployment:1||Uterine cancer:1||VARIABILITY:1||Vancomycinresistant enterococci:1||Variance Index Score:1||Vascular causes of cognitive impairment:1||Visfatin:1||Vitamin K Antagonist:1||Volume Threshold:1||WHO 2h criteria:1||Warfarin:1||Workers&apos:1||ablation:1||academic achievement:1||acupuncture:1||acute ischaemic stroke:1||acute minor stroke:1||acutephase protein:1||adherence:1||adiponectin:1||adiposity:1||age distribution:1||aging:1||air pollution:1||allcause mortality:1||anchor design:1||antioxidant activity:1||antiplatelet agents:1||antiplatelet drugs:1||arrhythmias, cardiac:1||artificial:1||assessment tool:1||assessment, patient outcome:1||asymmetry:1||attenuated inversion recovery:1||azathioprine:1||basilar artery:1||bleeding:1||blood pressure variability:1||brain infarction:1||brain ischemia:1||brain macrobleed:1||breast, diagnosis:1||burden:1||cancer pain:1||cardiovascular disease (CVD):1||cardiovascular disease risk factors:1||cardiovascular diseases:1||carotid artery:1||carotid atherosclerosis:1||catheter:1||catheter ablation:1||central venous access:1||cerebral microbleeds:1||characteristic:1||chemotherapy:1||childhood obesity:1||children:1||cholinergic fibers:1||chronic low back pain:1||clinical inertia:1||clinical trials:1||clopidogrelaspirin:1||colorectal cancer:1||comparative effectiveness research:1||comparative study:1||compensation:1||complications:1||computed tomography angiography:1||congenital:1||coronary angiography:1||coronary artery bypass:1||coronary artery disease:1||coronary atherosclerosis:1||coronary heart disease:1||coronary physiology:1||coronary stents:1||crosssectional survey:1||cytokine:1||cytotoxicity:1||dementia:1||demography:1||diabetes mellitus:1||diagnosis
Breast:1||diagnostic test accuracy:1||direct oral anticoagulants:1||disparity:1||dissection:1||dolichoectasia:1||dopamine D4 receptor:1||dripandship:1||drug utilization review:1||drugeluting stents:1||dual antiplatelets:1||ducts:1||early neurological deterioration:1||echocardiography:1||embolism:1||emergency care:1||endovascular therapy:1||factor analysis:1||falls:1||followup studies:1||fractional flow reserve:1||functional outcome:1||gastrointestinal risk:1||generalized estimating equation:1||geometric factors:1||ghrelin:1||glaucoma management:1||glenoid component:1||groupbased trajectory model:1||guideline:1||habits:1||health care:1||health inequality:1||healthy lifestyle:1||hemoglobin:1||hemoglobins:1||hemostatic:1||heparin:1||hepatocellular:1||hepatocellular carcinoma:1||history of intracerebral hemorrhage:1||hospice:1||hospital volume:1||humans:1||impaired glucose tolerance:1||incidence rate:1||infection control:1||inferior tilt:1||inflammation:1||inflammatory bowel disease:1||infliximab:1||insulinresistance:1||intention to treat (ITT):1||interleukin 6:1||internetbased study:1||intracerebral haemorrhage:1||intracerebral hemorrhage:1||intracranial arterial disease:1||intracranial arterial occlusion:1||intracranial arteriosclerosis:1||intracranial hemorrhage:1||intracranial stenosis:1||intravenous thrombolysis:1||ischaemic stroke:1||ischemia:1||ischemic attack, transient:1||isolated diastolic hypertension:1||isolated systolic hypertension:1||lacunar infarct:1||lacunar stroke:1||large artery atherosclerosis:1||last observation carried forward (LOCF):1||left main coronary artery:1||lipids:1||liver cancer:1||longevity:1||low NIHSS score:1||lowdose tPA:1||lowmolecularweight heparin:1||lung:1||lung cancer:1||lymph node dissection:1||magnetic resonance image:1||management:1||matched pair design:1||memory dysfunction:1||metabolic syndrome X:1||migraine:1||mild stroke:1||mixed effects model repeated measure (MMRM):1||multicenter registry:1||multicenter studies:1||myelofibrosis:1||neural networks:1||neural pathways:1||neuropathic pain:1||nodenegative:1||noninferiority:1||none:1||nurses:1||nursing:1||occlusion:1||occupational stress:1||office worker:1||oral glucose tolerance test:1||pain:1||parenting:1||particulate matter:1||path analysis:1||patient satisfaction:1||patientreported outcomes:1||pediatric cardiac:1||pediatrics:1||penumbra:1||per protocol (PP):1||perfusion:1||perfusion imaging:1||personality traits:1||pharmacological targeted therapy:1||platelet aggregation inhibitors:1||postoperative pneumonia:1||postoperative radiation therapy:1||poststroke dementia:1||predictive value of tests:1||prehospital delay:1||prehypertension:1||previous fall experience:1||primary stability:1||productivity loss:1||progression:1||propensity score matching:1||proportional hazard models:1||proportional hazards models:1||prospective cohort study:1||prospective studies:1||pullout strength:1||pulmonary heart disease:1||pulse pressure:1||pulse wave:1||quality assessment:1||quality assurance:1||quantitative flow ratio:1||questionnaire:1||radioactive iodine treatment (RAI treatment):1||randomized clinical trial:1||randomized controlled trial:1||recurrent stroke:1||registries:1||registry:1||reliability:1||reverse total shoulder arthroplasty:1||risk assessment:1||risk score:1||ruxolitinib:1||safety:1||satisfaction:1||screening test:1||seconadry stroke prevention:1||sleep:1||stenosis:1||stenosis and cerebrovascular occlusion:1||stroke care:1||stroke classification:1||stroke registry:1||stroke subtype:1||surgery:1||suture anchor:1||symptomatic hemorrhagic transformation:1||syndrome:1||systemic inflammation:1||tea:1||telomere:1||telomere binding proteins:1||temporomandibular disorders:1||therapeutics:1||thrombectomy:1||thyroid cancer:1||thyroid gland:1||time:1||time in therapeutic range:1||time to treatment:1||timeseries analysis:1||timetotreatment:1||tissuetype plasminogen activator:1||topographic brain mapping:1||transcranial Doppler:1||transesophageal echocardiography:1||treatment:1||treatment duration:1||treatment intensification:1||treatment pattern:1||treatment satisfaction:1||trends:1||tuberculosis:1||tumor necrosis factor alpha:1||tumor necrosis factor inhibitor:1||type 2:1||ultrasound (US), technology:1||ultrasound(US):1||unplanned readmission:1||validity:1||vascular cognitive impairment:1||vascular death:1||vascular dementia:1||vascular event:1||vascular event rate:1||vascular stiffness:1||venous thromboembolism:1||vocal cord fixation:1||vulnerable populations:1||warfarin:1||weight management:1||white blood cell count:1||white matter:1||white matter disease:1||white matter lesion:1||work tenure:1||감각처리능력:1||구강 악습관:1||근거중심의학(Evidencebased Medicine) 무작위배정임상실험 일차진단일차진료:1||기대 수명:1||내독소:1||당뇨병:1||디하이드로에피안드로스테론:1||렙틴:1||마약성 진통제:1||말기 환자:1||말기신부전증:1||말기암환자:1||발달장애:1||발생률:1||보완대체요법:1||부신 기능 저하:1||불안증상:1||비스파틴:1||사망률:1||생존:1||생존분석:1||생존율:1||선형 모형:1||식욕부진:1||실명 등 중증 장애를 유발할 수 있는 대표적인 만성질환이다1:1||아로마자가치료:1||아로마테라피:1||암성통증:1||약물치료:1||여명 예측:1||예후:1||우울:1||운동기술:1||유방암환자:1||의료비:1||의사 가능도:1||작업수행기술:1||제5의 활력징후:1||종양:1||직무스트레스:1||처리기술:1||최근 전세계적으:1||측두하악장애:1||통증:1||하이드로코티손:1||합병증에 대한 조기대처 등 적절한 관리를 통:1||호스피스 간호:1||혼합 모형:1||18% . 34%:1||2). 하지만 주기적 모니터링과 생활습관 개선:1||25hydroxyvitamin D:1||3).말기 신부전증 (End stage renal disease:1||37(1):1725(Multinational Corporation)2 . (home country) (hostcountry) . 1998 UN(World Investment Report) 44:1||47%:1||4AT:1||500 27 7.82%:1||547명의 환자를 대상으로 2003년도의 당뇨병성 족부질환의 발생률과 의료비용을 알아보고자 하였다. 연령군은 연말 기준으로 45세 미만:1||587:1||647명의 환자 중 사망자와 기존 유병자를 제외한 3:1||911:1||ADA fasting criteria:1||ADHD value:1||ANOVA:1||ANOVA estimation:1||ASSOCIATION:1||ATTACK:1||Acetonitrile:1||Acquisition:1||Acute Ischemic Stroke:1||Acute Stroke:1||Acute stroke intervention:1||Acute stroke therapy:1||Admission hyperglycemia:1||Admission route:1||Adrenal hyperplasia:1||Adrenal insufficiency:1||Aged 80 and over:1||Air pollution:1||Algorithm:1||Amonggroup variance component:1||Analgesics:1||Analysis of Variance:1||Angiotensin receptor antagonists:1||Angiotensinconverting enzyme inhibitors:1||Anorexia:1||Antenatal care:1||Antenatal education:1||Antiseizure medication:1||Anticoagulation:1||Antidepressive agents:1||Antiplatelet:1||Anxiety:1||Approximate confidence interval:1||Aroma therapy:1||Asia:1||Aspirin:1||Assessment Service:1||Asymptomatic:1||Atheroma:1||Atherosclerosis:1||Atherosclrerosis:1||Atmospheric pressure:1||Atrial Fibrillation:1||Attitude:1||BASELINE SEVERITY:1||Bacteremia:1||Balanced nested design:1||Barcelona Clinic Liver Cancer:1||Baths:1||Behavior:1||Brain Infarction: Recovery of Function:1||Brain imaging:1||Breakthrough cancer pain:1||Breakthrough pain:1||Breast:1||Breast
Breast neoplasms
Breast neoplasms:1||Creactive protein:1||CRCSK:1||CT:1||CTP:1||Cadaveric LT:1||Caffeine:1||Calcium:1||Cancer:1||Cardiac multidetector computed tomography:1||Cardiocerebrovascular Center:1||Cardiocerebrovascular disease:1||Cardioembolism:1||Carotid arteries:1||Carrier vehicle:1||Case profile:1||Casecontrol study:1||Cerebral Hemorrhage:1||Cerebral Infarction:1||Cerebral arteries:1||Cerebral artery disese:1||Cerebral hemorrhage:1||Cerebral ischemia:1||Cerebrovascular disease/stroke:1||Cerebrovascular disorders:1||Cerebrovascular occlusion:1||Characteristics:1||Children and adolescents:1||Chlorhexidine gluconate:1||Cholesterol:1||Cholesterol ester transfer proteins:1||Cholesterol, HDL:1||Chronic low back pain:1||Chronic total occlusion:1||Cilostazol:1||Civilization:1||Classical test theory:1||Classification:1||Clinical Outcomes:1||Clinical decision support system:1||Clinical performance examination:1||Clinical trial:1||Clinical trials:1||Coagulation disorder Jung Ho Park:1||Coffee:1||Cognition:1||Cognitive impairment:1||Cohort studies:1||Combined thrombolysis:1||Comet assay:1||Comorbidity:1||Comparative effectiveness research:1||Compliance:1||Continuity of care:1||Contour plots:1||Cost:1||Coverage probability:1||Crosssectional studies:1||Cut off membranes:1||Cyclooxygenase1:1||Cyclooxygenase2:1||Cytokine:1||DALY:1||DNA damage:1||DPPH:1||DWIASPECTS:1||Death:1||Dehydroepiandrosterone:1||Dementia:1||Developmental disability:1||Diabetes대상 및 방법1. 연구 대상1994년 12월부터 2000년 12월까지 (6년간) 당뇨병 상병코드 (E10:1||Diabetic foot ulcer:1||Diabetic retinopathy:1||Diffusion:1||Disease burden:1||Doseresponse:1||Doseresponse relationship:1||Double standard:1||Drugresistant epilepsy:1||Dual antiplatelet therapy:1||Dyslipidemias:1||E11:1||E12:1||E13:1||E14)를 주상병 혹은 부상병으로 하여 국민건강보험심사평가원에 1번도 급여 신청한 적이 없는 40세 이상 환자를 대상으로 하였다. 이들 환자 중 2001년부터 2003년까지 매년 첫 3개월 동안 (1월부터 3월까지) 당뇨병 상병코드를 주:1||END management:1||ESRD)은 당뇨병성 미세혈관합병증 중 사망으로 이어지는 가장 중요한 합병증으로:1||Early neurologic deterioration:1||Early vascular outcome:1||Economic factor:1||Eculizumab:1||Elastography:1||Emergency medical services:1||Endometrioid:1||Endotoxin:1||Endotoxins:1||Endovascular Therapy:1||

STATISTICS: Total View :9,857,988; Today View :1,222

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841) 82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE